Testagen 20mg by Dragon Pharma

Dragon Pharma Original Formula

Testagen

Lys-Glu-Asp-Gly Testicular Bioregulator20 mg vial
Class Khavinson Testicular Bioregulator
Sequence Lys-Glu-Asp-Gly (Tetrapeptide)
Target Tissue Testes / Leydig + Sertoli Cells
Suppression None (HPG)
Reconstitution Bacteriostatic Water
Form Subcutaneous Vial
Availability: In Stock
$68.00
Quantity
Shipping
Wishlist

Testagen — Testicular Bioregulator Tetrapeptide by Dragon Pharma

Testagen (Lys-Glu-Asp-Gly) is Dragon Pharma's formulation of the testicular Khavinson bioregulator tetrapeptide at 20mg per vial — the male reproductive system-targeted peptide in the Khavinson bioregulator series developed at the St. Petersburg Institute of Bioregulation and Gerontology. Like Ovagen (liver bioregulator) and Livagen (immune bioregulator), Testagen works through epigenetic DNA demethylation in its target tissue — in this case, testicular Leydig cells and Sertoli cells — potentially reactivating gene expression programmes suppressed by aging or AAS-induced testicular atrophy.

Also searched as: Testagen peptide, Lys-Glu-Asp-Gly bioregulator, Testagen testicular, Khavinson male bioregulator, Testagen Dragon Pharma.

Testagen in the Khavinson Framework — Testicular Tissue Specificity

Understanding Testagen requires the same Khavinson bioregulator framework as Ovagen and Livagen:

  • The Khavinson bioregulator series assigns each peptide to a specific tissue origin — Testagen is derived from testicular tissue extract. The peptide Lys-Glu-Asp-Gly was isolated and identified as a regulatory signal present in testicular tissue, acting preferentially on testicular cells when administered
  • The testes contain two functionally distinct cell populations relevant to Testagen: Leydig cells (interstitial cells that produce testosterone in response to LH) and Sertoli cells (which support sperm maturation in response to FSH)
  • Both cell types show age-related functional decline and epigenetic changes — Leydig cell testosterone output per cell declines with age; Sertoli cell number and function decrease, reducing spermatogenic support capacity
  • Testagen's proposed mechanism: direct interaction with chromatin in testicular cells, promoting DNA demethylation of gene promoters silenced by aging or functional suppression — potentially restoring the gene expression programmes of younger, more functional testicular cells

The AAS-Specific Mechanism — Leydig Cell Atrophy

Testagen's most specific and most underexplained application for AAS users:

  • AAS suppress LH production through HPG axis negative feedback — without LH stimulation, Leydig cells receive no signal to produce testosterone. Extended LH deprivation causes Leydig cells to undergo functional atrophy: they reduce in size, reduce steroidogenic enzyme expression, and become less responsive to LH stimulation even when natural LH production resumes post-cycle
  • This Leydig cell atrophy is the primary reason post-AAS testosterone recovery can be slow and incomplete — even when LH returns to baseline levels, the Leydig cells may not respond adequately because their gene expression machinery has been downregulated
  • HCG (LH mimetic) addresses this at the receptor level — stimulating LH receptors to maintain Leydig cell activity during cycles. But HCG works downstream of gene expression — it provides the signal, but if the Leydig cells' steroidogenic gene expression has been epigenetically downregulated, the response to that signal is blunted
  • Testagen theoretically addresses this at the epigenetic level — reactivating the steroidogenic gene expression in Leydig cells that LH deprivation has silenced. In this model, Testagen and HCG are complementary: HCG provides the stimulatory signal; Testagen ensures the receiving machinery (steroidogenic gene expression in Leydig cells) is restored to full capacity

Testagen vs HCG vs SERMs — Testicular Recovery Comparison

Agent Level of Action Mechanism What It Cannot Do
Testagen Leydig / Sertoli cell epigenome DNA demethylation → gene reactivation in testicular cells Does not stimulate testosterone production directly; no LH mimicry
HCG LH receptor on Leydig cells LH mimetic → stimulates testosterone synthesis Does not reactivate epigenetically silenced steroidogenic genes
Clomid / Nolvadex Hypothalamus / Pituitary ER blockade → restored LH/FSH production Cannot directly restore Leydig cell gene expression capacity
Kisspeptin Hypothalamus (above GnRH) GPR54 stimulation → pulsatile GnRH release Acts at top of axis; cannot restore Leydig cell function directly

Testagen in the Complete Khavinson Bioregulator Stack

Testagen completes the primary tissue-targeted Khavinson bioregulators available in the Dragon Pharma range:

  • Epitalon — pineal gland bioregulator; systemic anti-aging via telomerase activation and melatonin restoration
  • Livagen — immune/lymphoid bioregulator; epigenetic gene reactivation in lymphoid tissue
  • Ovagen — liver/GI bioregulator; epigenetic gene reactivation in hepatocytes and GI mucosa
  • Testagen — testicular bioregulator; epigenetic gene reactivation in Leydig and Sertoli cells

Used together, these four bioregulators provide Khavinson's multi-tissue epigenetic restoration approach — each targeting a different organ system's gene expression decline with aging or functional suppression.

Effects and Benefits

  • Leydig cell gene expression restoration — reactivation of steroidogenic gene programmes silenced by LH deprivation and aging
  • Sertoli cell functional support — gene expression restoration in spermatogenesis-supporting cells
  • Post-AAS testicular recovery support — complementary to HCG and SERM approaches, operating at the epigenetic rather than receptor level
  • Age-related hypogonadism support — age-associated Leydig cell functional decline is an epigenetic as well as hormonal phenomenon
  • No testosterone suppression — Testagen does not add exogenous hormones or suppress natural production
  • No PCT required after Testagen itself

Dosage and Administration

Protocol Dose Frequency Duration
Post-cycle testicular recovery 100–200 mcg Daily 10–20 day course during or after PCT
Age-related testicular support 100–200 mcg Daily 10–20 day course, 1-2× yearly

At 20mg per vial and 200mcg per dose, one vial provides 100 doses — multiple annual courses. Following the Khavinson course-based approach (10-20 day intensive protocols) rather than continuous use is standard for this class of bioregulators. Testagen is most logically used during or immediately after PCT, when the goal is maximising testicular functional recovery alongside the HPG axis restoration that SERMs and HCG provide. Reconstitute with bacteriostatic water. Store reconstituted vial refrigerated at 2-8°C for up to 28 days.

Side Effects

  • No significant side effects documented in Khavinson research — consistent with the Khavinson bioregulator safety profile across all tissue-specific peptides in the series
  • No hormonal effects — Testagen does not elevate or suppress testosterone directly; it works at the gene expression level in testicular cells
  • No PCT required after Testagen

Stacking Context

  • HCG 5000IU — LH receptor stimulation complementary to Testagen's Leydig cell gene reactivation; HCG provides the upstream hormonal signal; Testagen addresses the cellular gene expression capacity
  • Clomid or Nolvadex — HPG axis SERM recovery alongside Testagen's testicular-level support; comprehensive axis and gonadal recovery
  • Kisspeptin — hypothalamic-level axis restart alongside Testagen's testicular epigenetic support; the complete multi-level recovery stack covering hypothalamus (Kisspeptin), pituitary (SERM), testes via LH receptor (HCG), and testes via gene expression (Testagen)
  • Ovagen and Livagen — if using the full Khavinson bioregulator protocol alongside PCT, combining liver (Ovagen), immune (Livagen) and testicular (Testagen) tissue-specific support covers the three primary tissue systems affected by AAS cycles

"Testagen addresses testicular recovery at the epigenetic level — where HCG stimulates LH receptors and SERMs restore pituitary LH output, Testagen (Lys-Glu-Asp-Gly) reactivates the steroidogenic gene expression in Leydig cells that AAS-induced LH deprivation has epigenetically silenced."

Storage and Handling

Reconstitute with bacteriostatic water — add slowly along the vial wall and swirl gently. Store reconstituted vial refrigerated at 2-8°C for up to 28 days. Never freeze.

Please log in to write review.

Testagen (Lys-Glu-Asp-Gly) is the testicular tissue-targeted bioregulator in the Khavinson series — developed alongside Ovagen (liver), Livagen (immune) and Epitalon (pineal) at the St. Petersburg Institute of Bioregulation and Gerontology. Derived from testicular tissue extract, it works through the same epigenetic DNA demethylation mechanism as all Khavinson bioregulators, but with affinity specifically for Leydig cells and Sertoli cells in testicular tissue. It is the most AAS-relevant Khavinson bioregulator given the testicular atrophy that AAS cycles produce.

AAS suppress LH production through HPG axis negative feedback. Without LH stimulation, Leydig cells receive no signal to produce testosterone and undergo functional atrophy — they reduce in size, downregulate steroidogenic enzyme gene expression (StAR, CYP11A1, 3β-HSD, CYP17A1), and become less responsive to LH stimulation even when natural LH production resumes after the cycle. This Leydig cell atrophy at the gene expression level — not just receptor occupancy — is why testosterone recovery can be slow despite restored LH levels.

HCG and Testagen operate at different levels of the same problem. HCG provides an LH mimetic signal to LH receptors on Leydig cells — the upstream hormonal stimulus. If the Leydig cells' steroidogenic gene machinery has been epigenetically downregulated by prolonged LH deprivation, their response to that stimulus is blunted. Testagen's proposed mechanism — DNA demethylation to reactivate steroidogenic gene expression in Leydig cells — addresses the cellular responsiveness level. HCG provides the signal; Testagen theoretically restores the receiving machinery's capacity to respond.

The most logical timing is during and immediately after PCT. During the cycle, HCG maintains Leydig cell activity at the receptor level — Testagen can complement this at the gene expression level. During PCT, as SERM therapy restores natural LH production, Testagen supports the Leydig cell gene expression recovery that determines how effectively those cells respond to the returning LH signal. A 10-20 day Testagen course beginning with or shortly after PCT initiation covers the most critical recovery window.

No — Testagen does not produce testosterone and does not add any exogenous hormone. It is a tetrapeptide bioregulator that operates at the epigenetic level in testicular cells — potentially reactivating gene expression rather than directly stimulating testosterone synthesis. The testosterone increase, if achieved, comes from restored Leydig cell functional capacity responding to normal LH signals — endogenous, physiological production. No PCT is required for Testagen itself.

Yes — Epitalon (pineal), Livagen (immune), Ovagen (liver) and Testagen (testicular) target different tissues through the same mechanism. During and after AAS cycles, all four tissue systems are affected: the pineal gland's circadian regulation is disrupted, immune function is suppressed, the liver faces hepatotoxic stress from oral AAS, and the testes undergo functional atrophy. Running all four Khavinson bioregulators simultaneously provides tissue-specific epigenetic support across all four systems — a comprehensive multi-tissue recovery approach.